[Influence of immunovac-VP-4 therapy on innate immunity effectors in patients with darier erythema annulare centrifugum]

Zh Mikrobiol Epidemiol Immunobiol. 2013 Nov-Dec:(6):87-94.
[Article in Russian]

Abstract

Aim: Detection of features of functioning ofinnate and adaptive immunity pathways in patients with Darier erythema annulare centrifugum (EAC).

Materials and methods: 14 EAC patients aged 14 - 52 years were examined. The patients were ranked based on therapy variant. The first group consisted of 6 patients who had received Immunovac-VP-4 (Immunovac) against the background of basic therapy; the second group (4 patients) received cagocel against the background of basic therapy; the third group (4 patients) received only basic therapy; the group of healthy individuals consisted of 15 individuals. All the patients had the level ofcytokines in blood sera determined by solid-phase EIA by using Biosource (Austria) test-systems. Evaluation of TLR expression in peripheral blood mononuclear lymphocytes and keratinocytes was carried out by flow cytometry method by using monoclonal antibodies (Catlag Laboratories, USA) against the corresponding antigens; evaluation of content of lymphocyte subpopulations in blood was carried out by using monoclonal antibodies by flow cytometry method on FacsCalibur flow cytometer (Becton Dickinson, USA).

Results: Immunotherapy by Immunovac and cagocel facilitated the increase of CD3+, CD4+, CD8+. Immunovac facilitated a significant increase ofinitially low values ofCD25+, CD95+ and normalization of CD72+; normalization of IgM level. Immunovac increased the level of serum IL-2, induced the increase of IFN-gamma synthesis in contrast to cagocel and basic therapy, the administration of those caused its decrease. TGF-beta increased during the course of Immunovac immunotherapy and decreased during basic therapy. In the course of basic therapy a significant increase of initially high level ofcytokine IL-I beta was observed.

Conclusion: Immunovac therapy resulted in correction of content of lymphocyte populations, sera cytokines, facilitating the normalization of immunocompetent cell proliferation processes, activation of NK-cells, macrophages and at the same time suppression of DTH reactions. Immunovac facilitated the enhancement ofTLR3, 9 expression in the skin that indicates the inclusion ofintracellular receptor mechanisms of innate immunity.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Antigens, CD / blood
  • Antigens, CD / immunology
  • Antigens, Differentiation, B-Lymphocyte / blood
  • Antigens, Differentiation, B-Lymphocyte / immunology
  • Bacterial Vaccines / administration & dosage*
  • Cytokines / blood
  • Cytokines / immunology
  • Darier Disease* / blood
  • Darier Disease* / immunology
  • Darier Disease* / therapy
  • Erythema* / blood
  • Erythema* / immunology
  • Erythema* / therapy
  • Female
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / immunology
  • Gossypol / administration & dosage
  • Gossypol / analogs & derivatives*
  • Humans
  • Immunity, Innate / drug effects*
  • Immunoglobulin M / blood
  • Immunoglobulin M / immunology
  • Immunotherapy*
  • Interferon-gamma / blood
  • Interferon-gamma / immunology
  • Keratinocytes / immunology
  • Keratinocytes / metabolism
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Male
  • Middle Aged
  • Toll-Like Receptor 3 / biosynthesis
  • Toll-Like Receptor 3 / immunology
  • Toll-Like Receptor 9 / biosynthesis
  • Toll-Like Receptor 9 / immunology
  • Vaccines, Combined / administration & dosage

Substances

  • Antigens, CD
  • Antigens, Differentiation, B-Lymphocyte
  • Bacterial Vaccines
  • CD72 protein, human
  • Cytokines
  • IFNG protein, human
  • Immunoglobulin M
  • TLR3 protein, human
  • TLR9 protein, human
  • Toll-Like Receptor 3
  • Toll-Like Receptor 9
  • VP-4 vaccine
  • Vaccines, Combined
  • cagocel-1
  • Interferon-gamma
  • Gossypol